GMAB
Price:
$32.02
Market Cap:
$126.95B
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating sol...[Read more]
Industry
Biotechnology
IPO Date
2009-06-01
Stock Exchange
NASDAQ
Ticker
GMAB
According to Genmab A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 119.65B. This represents a change of 43.62% compared to the average of 83.31B of the last 4 quarters.
The mean historical Enterprise Value of Genmab A/S over the last ten years is 105.22B. The current 119.65B Enterprise Value has changed 11.27% with respect to the historical average. Over the past ten years (40 quarters), GMAB's Enterprise Value was at its highest in in the December 2022 quarter at 182.96B. The Enterprise Value was at its lowest in in the September 2015 quarter at 35.46B.
Average
105.22B
Median
88.77B
Minimum
52.82B
Maximum
183.01B
Discovering the peaks and valleys of Genmab A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 165.00%
Maximum Annual Enterprise Value = 183.01B
Minimum Annual Increase = -30.80%
Minimum Annual Enterprise Value = 52.82B
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 87.64B | -30.80% |
| 2023 | 126.65B | -30.80% |
| 2022 | 183.01B | 11.96% |
| 2021 | 163.46B | 6.42% |
| 2020 | 153.59B | 70.83% |
| 2019 | 89.91B | 44.46% |
| 2018 | 62.24B | -1.24% |
| 2017 | 63.01B | -9.89% |
| 2016 | 69.93B | 32.39% |
| 2015 | 52.82B | 165.00% |
The current Enterprise Value of Genmab A/S (GMAB) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
132.43B
5-year avg
142.87B
10-year avg
105.22B
Genmab A/S’s Enterprise Value is greater than Incyte Corporation (17.30B), greater than United Therapeutics Corporation (20.29B), greater than Royalty Pharma plc (24.37B), greater than Tenet Healthcare Corporation (28.86B), greater than Illumina, Inc. (21.09B), greater than Quest Diagnostics Incorporated (26.53B), greater than Roivant Sciences Ltd. (13.59B), greater than Summit Therapeutics Inc. (13.77B), greater than Zimmer Biomet Holdings, Inc. (25.28B), greater than Exelixis, Inc. (11.70B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 17.30B | $19.72B | |
| 20.29B | $21.63B | |
| 24.37B | $17.00B | |
| 28.86B | $18.64B | |
| 21.09B | $19.56B | |
| 26.53B | $20.58B | |
| 13.59B | $14.73B | |
| 13.77B | $14.00B | |
| 25.28B | $18.46B | |
| 11.70B | $11.90B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Genmab A/S's Enterprise Value?
What is the highest Enterprise Value for Genmab A/S (GMAB)?
What is the 3-year average Enterprise Value for Genmab A/S (GMAB)?
What is the 5-year average Enterprise Value for Genmab A/S (GMAB)?
How does the current Enterprise Value for Genmab A/S (GMAB) compare to its historical average?